

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORLED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

CLAIMS

1. A compound of formula (I)




and salts and solvates thereof, in which:

R⁰ represents hydrogen, halogen or C₁₋₆ alkyl;


R¹ represents hydrogen, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, haloC₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkylC₁₋₃alkyl, arylC₁₋₃alkyl or heteroarylC₁₋₃alkyl;

R² represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally



substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R³ represents hydrogen or C₁₋₃ alkyl, or R¹ and R³ together represent a 3- or 4- membered alkyl or alkenyl chain.

2. A compound of formula (Ia)




and salts and solvates thereof, in which:

R⁰ represents hydrogen, halogen or C₁₋₆ alkyl;

R¹ represents hydrogen, C₁₋₆alkyl, haloC₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkylC₁₋₃alkyl, arylC₁₋₃alkyl or heteroarylC₁₋₃alkyl; and

R² represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally



substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen.


3. A compound according to Claim 1 or 2, wherein R^o represents hydrogen.

4. A compound according to any of Claims 1 to 3, wherein R¹ represents hydrogen, C₁₋₄alkyl, haloC₁₋₄alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylmethyl, pyridylC₁₋₃alkyl, furylC₁₋₃alkyl or optionally substituted benzyl.

5. A compound according to any of Claims 1 to 3, wherein R¹ and R³ together represent a 3-membered alkyl chain.


6. A compound according to any of Claims 1 to 4, wherein R³ represents hydrogen.

7. A compound according to any of Claims 1 to 6, wherein R² represents an optionally substituted benzene, thiophene, furan, pyridine or naphthalene



ring or an optionally substituted bicyclic ring where n is 1 or 2 and X and Y are each CH₂ or O.

8. A cis isomer of formula (I) represented by formula (Ib)



and mixtures thereof with its cis optical enantiomer, including racemic mixtures, and salts and solvates of these compounds in which R⁰ is hydrogen or halogen and R¹, R² and R³ are as defined in any preceding claim.

5

9. Cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole-1,4-dione;
Cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzo[b]furan-5-yl)-2-methyl-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole -1,4-dione;
Cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-methyl-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole -1,4-dione;
Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methylphenyl)-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole -1,4-dione;
(6R, 12aR)-2,3,6,7,12,12a-Hexahydro-2-isopropyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole -1,4-dione;
(6R, 12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopentyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole -1,4-dione;
(6R, 12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopropylmethyl-6-(4-methoxyphenyl)-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole -1,4-dione;
(6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methyl-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole -1,4-dione;
(6R, 12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole-1,4-dione;
(6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole-1,4-dione;
(5aR, 12R, 14aS)-1,2,3,5,6,11,12,14a-Octahydro-12-(3,4-methylenedioxyphenyl)-pyrrolo[1'', 2'' : 4', 5']pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole-5-1,4-dione;
and physiologically acceptable salts and solvates thereof.

30


10. (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1' : 6, 1]pyrido[3,4-b]indole -1,4-dione;
and physiologically acceptable salts and solvates thereof.

10065146, 626503

- 5
11. A compound according to any of Claims 1 to 10, for use in the treatment of stable, unstable and variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.
- 10
12. Use of a compound according to any of Claims 1 to 10, for the manufacture of a medicament for the treatment of stable, unstable and variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.
- 15
13. A method of treating stable, unstable and variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility, in a human or non-human animal body, which method comprises administering to said body a therapeutically effective amount of a compound according to any of Claims 1 to 10.
- 20
- 25
14. A pharmaceutical composition comprising a compound of the according to any of Claims 1 to 10, together with a pharmaceutically acceptable diluent or carrier therefor.
- 30
15. A process of preparing a pharmaceutical composition comprising a compound according to any of Claims 1 to 10, which process comprises mixing said compound together with a pharmaceutically acceptable diluent or carrier therefor.
- 35


16. A process of preparing a compound of formula (I), which process comprises:

5 a process (A) for preparing a compound of formula (I), wherein R^3 represents hydrogen which process (A) comprises treating a compound of formula (II)



10 in which Alk represents C_{1-6} alkyl and Hal is a halogen atom, with a primary amine R^1NH_2 ; or


15 a process (B) for preparing a compound of formula (I), wherein R^1 and R^3 together represent a 3- or 4-membered alkyl or alkenyl chain, which process (B) comprises cyclisation of a compound of formula (VIII)



20 wherein Alk represents C_{1-6} alkyl and R^1 and R^3 together represent a 3- or 4-membered chain both as defined above; or

a process (C) for preparing a compound of formula (I) wherein R^3 represents C_{1-3} alkyl, which process (C) comprises cyclisation of a compound of formula (X)

83



wherein Alk represents C₁₋₆alkyl and R⁵ represents C₂₋₅alkyl, substituted at C₁ by a halogen atom; or

process (A), (B) or (C) as hereinbefore described followed by

- i) an interconversion step; and/or either
- ii) salt formation; or
- iii) solvate formation.

17. Compounds of formulae (II), (III), (V), (VI), (VII), (VIII) and (X), with the exception for compounds (III), (V), (VI) and (VII) wherein R° is hydrogen, R² is phenyl and Alk is methyl.

add
A2